BLACKSBURG, VA – Intrexon Corporation has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
The IPO, which Intrexon filed as an “emerging growth company,” is designed to raise $125 million and trade on the New York Stock Exchange under the symbol XON. The number of shares to be offered and the price range for the offering have not yet been determined.
Earlier this month the synthetic biology company broadened its existing collaboration with Fibrocell Science. This move along with a number of other collaborations is designed to align its industry markets to focus on four key sectors: Health, Food, Energy and Environment.
Net proceeds from the initial public offering would fund continued investment in the company’s research and development platforms as well as push additional collaboration agreements, according to the filing.
J.P. Morgan and Barclays will serve as joint book-running managers in the proposed offering.